keyword
MENU ▼
Read by QxMD icon Read
search

Thyroid cancer

keyword
https://www.readbyqxmd.com/read/29241201/cot-death-history-of-an-iatrogenic-disaster
#1
Michael Obladen
Since antiquity, cot death has been explained as accidental suffocation, overlaying, or smothering. Parents were blamed for neglect or drunkenness. A cage called arcuccio was invented around 1570 to protect the sleeping infant. Up to the 19th century, accidents were registered as natural causes of death. From 1830, accidental suffocation became unacceptable for physicians and legislators, and "natural" explanations for the catastrophe were sought, with parents being consoled rather than blamed. Two assumed causes had serious consequences: thymus hyperplasia was irradiated, causing thyroid cancer, and the concept of central apnea was widely accepted, which led to home monitors and distracted from epidemiological evidence...
December 15, 2017: Neonatology
https://www.readbyqxmd.com/read/29240540/patient-age-associated-mortality-risk-is-differentiated-by-braf-v600e-status-in-papillary-thyroid-cancer
#2
Xiaopei Shen, Guangwu Zhu, Rengyun Liu, David Viola, Rossella Elisei, Efisio Puxeddu, Laura Fugazzola, Carla Colombo, Barbara Jarzab, Agnieszka Czarniecka, Alfred K Lam, Caterina Mian, Federica Vianello, Linwah Yip, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Christine J O'Neill, Mark S Sywak, Roderick Clifton-Bligh, Bela Bendlova, Vlasta Sýkorová, Mingzhao Xing
Purpose For the past 65 years, patient age at diagnosis has been widely used as a major mortality risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is generally applicable, particularly in patients with different BRAF genetic backgrounds, is unclear. The current study was designed to test whether patient age at diagnosis is a major mortality risk factor. Patients and Methods We conducted a comparative study of the relationship between patient age at diagnosis and PTC-specific mortality with respect to BRAF status in 2,638 patients (623 men and 2,015 women) with a median age of 46 years (interquartile range, 35 to 58 years) at diagnosis and a median follow-up time of 58 months (interquartile range, 26 to 107 months)...
December 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29240539/is-braf-v600e-mutation-the-explanation-for-age-associated-mortality-risk-in-patients-with-papillary-thyroid-cancer
#3
Megan R Haymart
No abstract text is available yet for this article.
December 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29239041/hereditary-and-familial-thyroid-tumours
#4
REVIEW
Julie Guilmette, Vania Nosé
The worldwide incidence of thyroid malignancies has been increasing rapidly. Sensitive imaging modalities and early detection of thyroid lesions have made thyroid cancers the most rapidly increasing cancers in the USA in 2017 (SEER Cancer Facts, 2017). Clinical awareness of potential risk factors, such as inherited thyroid cancers, has allowed earlier recognition of more vulnerable population clusters. Hereditary thyroid neoplasms arising from calcitonin-producing C cells are known as familial medullary thyroid carcinomas (FMTCs), and include well-documented syndromes such as multiple endocrine neoplasia IIA or IIB, and pure familial medullary thyroid carcinoma syndrome...
January 2018: Histopathology
https://www.readbyqxmd.com/read/29239040/molecular-pathology-of-thyroid-tumours-of-follicular-cells-a-review-of-genetic-alterations-and-their-clinicopathological-relevance
#5
REVIEW
Giorgia Acquaviva, Michela Visani, Andrea Repaci, Kerry J Rhoden, Dario de Biase, Annalisa Pession, Tallini Giovanni
Thyroid cancer is the most common endocrine malignancy. Knowledge of the molecular pathology of thyroid tumours originating from follicular cells has greatly advanced in the past several years. Common molecular alterations, such as BRAF p.V600E, RAS point mutations, and fusion oncogenes (RET-PTC being the prototypical example), have been, respectively, associated with conventional papillary carcinoma, follicular-patterned tumours (follicular adenoma, follicular carcinoma, and the follicular variant of papillary carcinoma/non-invasive follicular thyroid neoplasm with papillary-like nuclear features), and with papillary carcinomas from young patients and arising after exposure to ionising radiation, respectively...
January 2018: Histopathology
https://www.readbyqxmd.com/read/29239036/a-user-s-guide-to-non-invasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-niftp
#6
REVIEW
Yin P Hung, Justine A Barletta
The term non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was recently introduced to replace a subset of follicular variant of papillary thyroid carcinoma (FVPTC). The goal of this change was to promote more conservative management of these tumours and spare patients the psychological burden of a cancer diagnosis. The histological diagnosis of NIFTP is stringent: the tumour needs to demonstrate encapsulation or circumscription, a purely follicular architecture and the presence of nuclear features of papillary thyroid carcinoma, while lacking capsular and vascular invasion, a significant component of solid growth and high-grade features (increased mitotic activity and necrosis)...
January 2018: Histopathology
https://www.readbyqxmd.com/read/29238906/thyroid-dysfunctions-secondary-to-cancer-immunotherapy
#7
REVIEW
P Chalan, G Di Dalmazi, F Pani, A De Remigis, A Corsello, P Caturegli
BACKGROUND: Immunotherapy is a firmly established pillar in the treatment of cancer, alongside the traditional approaches of surgery, radiotherapy, and chemotherapy. Like every treatment, also cancer immunotherapy causes a diverse spectrum of side effects, collectively referred to as immune-related adverse events. OBJECTIVE: This review will examine the main forms of immunotherapy, the proposed mechanism(s) of action, and the incidence of thyroid dysfunctions. METHODS: A comprehensive MEDLINE search was performed for articles published up to March 30, 2017...
December 13, 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/29238222/the-burden-of-selected-cancers-in-the-us-health-behaviors-and-health-care-resource-utilization
#8
Laura Iadeluca, Jack Mardekian, Pratibha Chander, Markay Hopps, Geoffrey T Makinson
Objective: To characterize the disease burden among survivors of those cancers having the highest incidence in the US. Methods: Adult (≥18 years) survivors of the 11 most frequently diagnosed cancers were identified from publically available data sources, including the Surveillance Epidemiology and End Results 9 1973-2012, National Health Interview Survey 2013, and the Medical Expenditure Panel Survey 2011. Chi-square tests and one-way analyses of variance were utilized to assess differences between cancer survivors and non-cancer controls in behavioral characteristics, symptoms and functions, preventative screenings, and health care costs...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/29237802/phase-1-dose-escalation-study-of-anti-ctla-4-antibody-ipilimumab-and-lenalidomide-in-patients-with-advanced-cancers
#9
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M Tsimberidou, Jennifer J Wheler, David S Hong, Aung Naing, Gerald S Falchook, Michelle A Fanale, Maria E Cabanillas, Filip Janku
Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxicities (DLT) of the anti-CTLA-4 antibody ipilimumab (1.5-3mg/kg intravenously every 28 days x 4) and lenalidomide (10-25mg orally daily for 21 of 28 days until disease progression or unacceptable toxicity) in advanced cancers...
December 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29236327/pi3k-inhibitors-ic87114-inhibits-the-migration-and-invasion-of-thyroid-cancer-cell-in-vitro-and-in-vivo
#10
Yan Jiang, Shuai Hao, Wuguo Tian, Bo Gao, Xiaohua Zhang, Shu Zhang, Lingji Guo, Jie Yan, Donglin Luo
Thyroid cancer is currently the most common endocrine malignancies, and PI3K/Akt pathway play an important role during its initiation and development. IC87114 is an inhibitor of PI3K/Akt pathway. Little is known about the role of IC87114 in the initiation and progression of thyroid cancer. Here, we demonstrated that IC87114 significantly inhibited both the migration and invasion of thyroid cancer cells, which can be mediateded by inhibition of PI3K/Akt pathway.These results suggest that application of IC87114 may prove to be a particularly effective treatment for thyroid cancer...
December 13, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29236027/simvastatin-inhibits-cell-proliferation-and-migration-in-human-anaplastic-thyroid-cancer
#11
Mei-Chieh Chen, Yuan-Chin Tsai, Jen-Ho Tseng, Jr-Jiun Liou, Steve Horng, Heng-Ching Wen, Yu-Ching Fan, Wen-Bin Zhong, Sung-Po Hsu
Malignant human anaplastic thyroid cancer (ATC) is pertinacious to conventional therapies. The present study investigated the anti-cancer activity of simvastatin and its underlying regulatory mechanism in cultured ATC cells. Simvastatin (0-20 μM) concentration-dependently reduced cell viability and relative colony formation. Depletions of mevalonate (MEV) and geranylgeranyl pyrophosphate (GGpp) by simvastatin induced G1 arrest and increased apoptotic cell populations at the sub-G1 phase. Adding MEV and GGpp prevented the simvastatin-inhibited cell proliferation...
December 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29234902/correction-to-molecular-imaging-of-advanced-thyroid-cancer-iodinated-radiotracers-and-beyond
#12
Prasanna Santhanam, Lilja B Solnes, Steven P Rowe
The original version of this article unfortunately contained a mistake. The middle name of the author Steven B. Rowe is incorrect. The corrected name is Steven P. Rowe.
December 12, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29234677/metabolic-alterations-of-thyroid-cancer-as-potential-therapeutic-targets
#13
REVIEW
Domenico Ciavardelli, Maria Bellomo, Ada Consalvo, Caterina Crescimanno, Veronica Vella
Thyroid cancer (TC) is the most frequent endocrine tumor with a growing incidence worldwide. Besides the improvement of diagnosis, TC increasing incidence is probably due to environmental factors and lifestyle modifications. The actual diagnostic criteria for TC classification are based on fine needle biopsy (FNAB) and histological examination following thyroidectomy. Since in some cases it is not possible to make a proper diagnosis, classical approach needs to be supported by additional biomarkers. Recently, new emphasis has been given to the altered cellular metabolism of proliferating cancer cells which require high amount of glucose for energy production and macromolecules biosynthesis...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29234625/insight-into-differentiated-thyroid-cancer-gross-pathological-specimen-shrinkage-and-its-influence-on-tnm-staging
#14
Alexis Lacout, Emmanuel Chamorey, Juliette Thariat, Mostafa El Hajjam, Carole Chevenet, Renaud Schiappa, Pierre Yves Marcy
Introduction: This study aimed at comparing thyroid cancer staging when taking into account the differences between the "T" assessment" using ultrasound (US) and histopathological measurements. Material and Methods: This retrospective study included all consecutive differentiated follicular thyroid cancer (DTC) and medullary thyroid cancer (MTC) patients who underwent postoperative histopathological staging assessment at a single institution. Anaplastic thyroid carcinomas were excluded from the present study...
November 2017: European Thyroid Journal
https://www.readbyqxmd.com/read/29234622/impact-of-serum-tsh-and-anti-thyroglobulin-antibody-levels-on-lymph-node-fine-needle-aspiration-thyroglobulin-measurements-in-differentiated-thyroid-cancer-patients
#15
Marta Amaro da Silveira Duval, André Borsatto Zanella, Ana Patrícia Cristo, Carlo Sasso Faccin, Marcia Silva Graudenz, Ana Luiza Maia
Background: Thyroglobulin measurements in the washout of fine needle aspiration (FNA-Tg) are an excellent tool to detect lymph node (LN) metastases of differentiated thyroid carcinoma (DTC). Nevertheless, how to define the best cutoffs and the influence of potential confounders are still being discussed. Objective: To evaluate the accuracy of FNA-Tg measurement to detect DTC metastases and the influence of thyroid status and anti-thyroglobulin antibodies (TgAb)...
November 2017: European Thyroid Journal
https://www.readbyqxmd.com/read/29234267/incidental-detection-of-occult-thyroid-carcinoma-with-11c-choline-pet-ct-for-high-risk-prostate-cancer
#16
Adama Ouattara, Tiago Ribeiro de Oliveira, Serge Holz, Hannes Van den Bossche, David Strybol, Christophe Assenmacher, Wouter Everaerts, Gert De Meerleer, Steven Joniau
We report a case of a 65-year-old male patient with high-risk prostate cancer, re-staged with 11C-choline positron emission tomography/computed tomography (PET/CT) for prostate specific antigen recurrences 3 years after radical prostatectomy and adjuvant radiation therapy. In addition to 2 suspicious presacral lymph nodes which were resected and proven to be metastatic, PET/CT revealed a very high uptake in a calcified thyroid nodule. Evaluation with fine needle aspiration was suspicious for thyroid carcinoma and the patient underwent total thyroidectomy, confirming a non-metastatic encapsulated follicular variant of papillary thyroid carcinoma...
November 2017: Current Urology
https://www.readbyqxmd.com/read/29234152/lncrna-spry4-it-was-concerned-with-the-poor-prognosis-and-contributed-to-the-progression-of-thyroid-cancer
#17
Haoyu Zhou, Zhihua Sun, Songwei Li, Xiaofeng Wang, Xuejun Zhou
Long non-coding RNAs (lncRNAs) have been demonstrated to be critical regulators in tumorigenesis. LncRNA SPRY4-IT1 has been identified as critical regulator for hepatocellular carcinoma and ovarian cancer. However, the potential role and clinical value of SPRY4-IT1 in human thyroid cancer (TC) still remain unclear and need to be uncovered. Our current study was aimed to ascertain the biological role of expression of SPRY4-IT1 in TC tissues and cells. Our findings revealed that the level of SPRY4-IT1 was significantly upregulated in TC tissues and cell lines, which was correlated with poor prognosis...
December 12, 2017: Cancer Gene Therapy
https://www.readbyqxmd.com/read/29233840/microbiome-in-pten-hamartoma-tumor-syndrome
#18
Victoria Byrd, Ted M Getz, Roshan Padmanabhan, Hans Arora, Charis Eng
Germline PTEN mutations defining PTEN hamartoma tumor syndrome [PHTS] confer heritable predisposition to breast, endometrial, thyroid, and other cancers with known age-related risks, but it remains impossible to predict if any individual will develop cancer. In the general population, gut microbial dysbiosis has been linked to cancer, yet is unclear whether these are associated in PHTS patients. In this pilot study, we aimed to characterize microbial composition of stool, urine, and oral wash from 32 PTEN mutation-positive individuals using 16S rRNA-gene sequencing...
December 12, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29232305/braf-inhibitors-can-exert-control-of-disease-in-braf-t599i-mutated-melanoma-a-case-report
#19
Susanna Gallo, Valentina Coha, Daniela Caravelli, Paolo Becco, Tiziana Venesio, Alessandro Zaccagna, Elena Giacone, Federica Marenco, Alberto Pisacane, Manuela Racca, Loretta Gammaitoni, Massimo Aglietta, Fabrizio Carnevale-Schianca
BRAF signaling is involved in melanoma growth in more than half of metastatic patients. In the last few years, new drugs that block this pathway have significantly improved the outcomes of patients with metastatic melanoma. Ninety percent of BRAF mutations involve exon 15, and the most frequent, V600E, results from the amino acid change from valine (V) to glutamic acid (E). BRAF inhibitor treatments have shown a notable overall response rate and improvements in progression-free and overall survival. Rare BRAF mutations of codon 599 have been also described in a few patients with papillary thyroid cancer and melanoma...
December 11, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29231049/heart-rate-recovery-and-cancer-risk-prospective-cohort-study
#20
Yong Hyun Byun, Sang Yeun Kim, Yejin Mok, Youngwon Kim, Sun Ha Jee
PURPOSE: To determine the association between 2-minute heart rate recovery (HRR) and cancer risk. METHODS: Each participant (5379 women; 8485 men) provided HRR obtained from treadmill tests. The outcome was site-specific cancer. RESULTS: Over 9 years of follow-up, 630 cancer events (258 women) were accrued. Slower HRR was associated with increased thyroid cancer risk in women ( P for trend = .0121) and colorectal cancer risk in men ( P for trend = ...
December 1, 2017: Asia-Pacific Journal of Public Health
keyword
keyword
1085
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"